drugset / Trial / NCT00150319

An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

NCT00150319

Phase 1/2 Terminated 1 enrolled Pfizer
Non-randomizedSingle-groupOpen-label

Summary

This is a study to investigate the pharmacokinetics, safety and tolerability of intravenous voriconazole and SBECD in patients with moderate renal insufficiency

Timeline

Start
2005-06
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Voriconazole Small molecule Intravenous

Indications